<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02562703</url>
  </required_header>
  <id_info>
    <org_study_id>tVNS</org_study_id>
    <nct_id>NCT02562703</nct_id>
  </id_info>
  <brief_title>tVNS for Depression</brief_title>
  <official_title>Transcutaneous Vagus Nerve Stimulation for Treating Major Depressive Disorder: a Phase II, Randomized, Double-blind Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santa Casa Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santa Casa Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, randomized, sham controlled, clinical trial. This clinical trial has as
      primary objective to evaluate changes in depressive symptoms of a transcutaneous Vagus Nerve
      Stimulation (tVNS) treatment protocol for patients with moderate / severe depressive episode.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>â€¢ Hamilton Depressive Rating Scale version 17 items (HDRS-17)</measure>
    <time_frame>Change from baseline in depressive symptoms at 2 weeks</time_frame>
    <description>This clinical trial has as primary objective to evaluate the effect of the tVNS on depressive symptoms measured by the Hamilton Depressive Rating Scale version 17 items (HDRS-17) in patients with moderate / severe depressive episode.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>ACTIVE tVNS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tVNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed over the mastoid process bilaterally. The study protocol will follow the rational of our previous trials with TNS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHAM tVNS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>tVNS will be applied by the external simulator (Monarch). The stimulation will be turned off after 60 seconds following previous trials.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcutaneous Vagus Nerve Stimulation</intervention_name>
    <description>tVNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed over the mastoid process bilaterally. The study protocol will follow the rational of our previous trials with TNS.</description>
    <arm_group_label>ACTIVE tVNS</arm_group_label>
    <arm_group_label>SHAM tVNS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients between 18 and 69 years

          2. patients with a diagnosis of depression according to the SCID

          3. score greater than or equal to 18 on the Hamilton Rating Scale 17-item version
             (equivalent to moderate or severe depressive episode)

          4. agreement to participate in the study as recommended in the IC.

        Exclusion Criteria:

          1. patients with psychiatric indication for hospitalization

          2. patients with psychiatric comorbidity

          3. patients with a diagnosis of personality disorder

          4. presence of severe neurological or medical diseases such as neoplasms in activity,
             neurodegenerative diseases and chronic diseases uncompensated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alisson P Trevizol, MD</last_name>
    <email>alisson.trevizol@hotmail.com</email>
  </overall_contact>
  <results_reference>
    <citation>Trevizol AP, Sato IA, Bonadia B, Liquidato BM, Barros MD, Cordeiro Q, Shiozawa P. Trigeminal Nerve Stimulation (TNS) for Major Depressive Disorder in Pregnancy: A Case Study. Brain Stimul. 2015 Sep-Oct;8(5):988-9. doi: 10.1016/j.brs.2015.07.034. Epub 2015 Jul 23.</citation>
    <PMID>26358492</PMID>
  </results_reference>
  <results_reference>
    <citation>Shiozawa P, Duailibi MS, da Silva ME, Cordeiro Q. Trigeminal nerve stimulation (TNS) protocol for treating major depression: an open-label proof-of-concept trial. Epilepsy Behav. 2014 Oct;39:6-9. doi: 10.1016/j.yebeh.2014.07.021. Epub 2014 Aug 23.</citation>
    <PMID>25150403</PMID>
  </results_reference>
  <results_reference>
    <citation>Cook IA, Schrader LM, Degiorgio CM, Miller PR, Maremont ER, Leuchter AF. Trigeminal nerve stimulation in major depressive disorder: acute outcomes in an open pilot study. Epilepsy Behav. 2013 Aug;28(2):221-6. doi: 10.1016/j.yebeh.2013.05.008. Epub 2013 Jun 14.</citation>
    <PMID>23773978</PMID>
  </results_reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2015</study_first_submitted>
  <study_first_submitted_qc>September 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2015</study_first_posted>
  <last_update_submitted>September 25, 2015</last_update_submitted>
  <last_update_submitted_qc>September 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Santa Casa Medical School</investigator_affiliation>
    <investigator_full_name>Pedro Shiozawa</investigator_full_name>
    <investigator_title>Coordinator - Interdisciplinary Center for Clinical Neuromodulation</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

